Skip to main content
Top
Published in: Breast Cancer Research 2/2005

01-06-2005 | Oral Presentation

Genetic and epigenetic changes in early carcinogenesis

Author: TD Tlsty

Published in: Breast Cancer Research | Special Issue 2/2005

Login to get access

Excerpt

Studies of human epithelial cells and fibroblasts from healthy individuals are providing novel insights into how early epigenetic and genetic events affect genomic integrity and fuel carcinogenesis. Key epigenetic changes, such as the hypermethylation of the p16 promoter sequences, create a previously unappreciated pre-clonal phase of tumorigenesis in which a subpopulation of epithelial cells is positioned for progression to malignancy [1]. These key changes precede the clonal outgrowth of premalignant lesions and occur frequently in healthy, disease-free individuals [2]. Prior work from our laboratory has shown that surrounding stroma can dramatically influence tumorigenesis. Proper stromal-epithelial interactions can actually suppress the expression of preneoplastic phenotypes in epithelial cells and, conversely, altered stromal-epithelial interactions can promote the probability that preneoplastic lesions progress to malignancy [3]. Understanding more about these early events should provide novel molecular candidates for prevention and therapy of cancer. …
Literature
1.
2.
go back to reference Cancer Cell. 2004, 5: 263-10.1016/S1535-6108(04)00023-6. Cancer Cell. 2004, 5: 263-10.1016/S1535-6108(04)00023-6.
Metadata
Title
Genetic and epigenetic changes in early carcinogenesis
Author
TD Tlsty
Publication date
01-06-2005
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 2/2005
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1057

Other articles of this Special Issue 2/2005

Breast Cancer Research 2/2005 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine